Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 609: Phase I Study of N6LS With or Without rHuPH20 in Healthy Adults
NCT03538626Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2018
- Primary completion
- Aug 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, open-label trial of VH3810109 in human immunodeficiency virus infection (HIV) (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 3 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 3 days and 4 more. Started Jun 2018; status: completed.
02
Drugs
VH3810109
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03538626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03538626.